Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback